Clinical Trial Search

Primary: Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) and AE Leading to Discontinuation (AELD) — 1; 1; 1; 5 Participants

Primary: Number of Participants Who Experienced an Adverse Event (All Types/Grades) Within a Time Frame up to 24 Hours Following the Transfusion. — 2; 3 Participants

Primary: Number of Participants DLT in Arm 1 in Dose Escalation Phase — 0; 0; 2; 1 Participants

Primary: The Number of Participants That Experience Grade 2-4 Acute GVHD (Graft Versus Host Disease) by Day 100 — 2 participants

Primary: Overall Survival at 6 Months Post-transplant in Patients Receiving a Partially-matched Related Donor Allogeneic Transplant After Reduced-intensity Conditioning — 22…

Primary: Chronic GVHD Requiring Systemic Immunosuppressive Treatment — 16 percent of patients

Primary: Safety and Tolerability of HSC835 for Clinical Use Were Measured by Infusional Toxicity (Within First 48 Hours After Transplant) and Absence of Graft Failure After 32…

Primary: Graft-Versus-Host Disease-Free, Relapse-Free Survival (GRFS) at 1 Year — 53; 84 percentage of survival probability

Primary: Evaluate the Risk of Transplant Related Mortality. — 20 percentage of participants

Primary: Safety Assessed by Adverse Events — 3; 3; 4; 4 participants

Primary: Number of Patients With Grade III-IV Acute Graft-versus-host Disease (GVHD) Post-transplant — 2; 0; 0 Participants

Primary: Number of Donors That Mobilize ≥ 2 x 10^6 CD34+ Cells/kg of Recipients Weight After a Single Injection of BL-8040 After no More Than Two Leukapheresis Collections (Arm 1…

Primary: Percentage of Participants With a Dose-Limiting Toxicity (DLT) — 4.8; 2.4; 0.0; 5.0 Percentage of Participants

Primary: Acute Toxicity Associated With the Infusion of NiCord — 0 Participants

Primary: Number of Participants With Dose-Limiting Toxicity (DLT) — 1; 2; 0; 1 participants